Abstract
BACKGROUND AND OBJECTIVE
To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA).
PATIENTS AND METHODS
A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept.
RESULTS
Eyes received an average of 16 prior injections (range: three injections to 31 injections; median: 17 injections). The mean central subfoveal thickness (CST) improved from 453 µm at the time of first anti-vascular endothelial growth factor (VEGF) injection (range: 304 µm to 686 µm; median: 429 µm), to 374 µm at the time of the switch to aflibercept (range: 267 µm to 547 µm; median: 361 µm; P = .02), to 332 µm after the first aflibercept injection (range: 242 µm to 545 µm; median: 318 µm; P < .001). Visual acuity improved after switching to aflibercept at the first follow-up visit (logMAR 0.40 [Snellen equivalent 20/50]) to logMAR 0.35 (Snellen equivalent 20/45) (P = .044).
CONCLUSIONS
In eyes with persistent DME treated with ranibizumab and/or bevacizumab, switching to aflibercept may further improve macular thickness. Given the cost difference between the three drugs, a randomized trial evaluating a stepwise approach may be worthwhile. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:836-839.].
TY - JOUR
T1 - Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
AU - Shah,Chirag P,
AU - Heier,Jeffrey S,
PY - 2016/05/15/received
PY - 2016/07/01/accepted
PY - 2016/9/16/entrez
PY - 2016/9/16/pubmed
PY - 2017/7/6/medline
SP - 836
EP - 9
JF - Ophthalmic surgery, lasers & imaging retina
JO - Ophthalmic Surg Lasers Imaging Retina
VL - 47
IS - 9
N2 - BACKGROUND AND OBJECTIVE: To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept. RESULTS: Eyes received an average of 16 prior injections (range: three injections to 31 injections; median: 17 injections). The mean central subfoveal thickness (CST) improved from 453 µm at the time of first anti-vascular endothelial growth factor (VEGF) injection (range: 304 µm to 686 µm; median: 429 µm), to 374 µm at the time of the switch to aflibercept (range: 267 µm to 547 µm; median: 361 µm; P = .02), to 332 µm after the first aflibercept injection (range: 242 µm to 545 µm; median: 318 µm; P < .001). Visual acuity improved after switching to aflibercept at the first follow-up visit (logMAR 0.40 [Snellen equivalent 20/50]) to logMAR 0.35 (Snellen equivalent 20/45) (P = .044). CONCLUSIONS: In eyes with persistent DME treated with ranibizumab and/or bevacizumab, switching to aflibercept may further improve macular thickness. Given the cost difference between the three drugs, a randomized trial evaluating a stepwise approach may be worthwhile. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:836-839.].
SN - 2325-8179
UR - https://www.unboundmedicine.com/medline/citation/27631479/Aflibercept_for_Diabetic_Macular_Edema_in_Eyes_Previously_Treated_With_Ranibizumab_and/or_Bevacizumab_May_Further_Improve_Macular_Thickness_
L2 - https://www.healio.com/doiresolver?doi=10.3928/23258160-20160901-06
DB - PRIME
DP - Unbound Medicine
ER -
